Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.

MLA

van Dijk, Anneke D., et al. “Bortezomib Is Significantly Beneficial for de Novo Pediatric AML Patients with Low Phosphorylation of the NF-ΚB Subunit RelA.” Proteomics. Clinical Applications, vol. 16, no. 2, Mar. 2022, p. e2100072. EBSCOhost, https://doi.org/10.1002/prca.202100072.

APA

van Dijk, A. D., Hoff, F. W., Qiu, Y., Gerbing, R. B., Gamis, A. S., Aplenc, R., Kolb, E. A., Alonzo, T. A., Meshinchi, S., Jenkins, G. N., de Bont, E. S. J. M., Kornblau, S. M., & Horton, T. M. (2022). Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA. Proteomics. Clinical Applications, 16(2), e2100072. https://doi.org/10.1002/prca.202100072

Chicago

van Dijk, Anneke D, Fieke W Hoff, Yihua Qiu, Robert B Gerbing, Alan S Gamis, Richard Aplenc, E Anders Kolb, et al. 2022. “Bortezomib Is Significantly Beneficial for de Novo Pediatric AML Patients with Low Phosphorylation of the NF-ΚB Subunit RelA.” Proteomics. Clinical Applications 16 (2): e2100072. doi:10.1002/prca.202100072.